{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:31:43Z","timestamp":1761863503519,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40121-015-0102-x","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T22:24:04Z","timestamp":1452291844000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports"],"prefix":"10.1007","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-8019","authenticated-orcid":false,"given":"Julie","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubanke","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Frater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"key":"102_CR1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Pre-exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;363:2587\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"102_CR2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"9883","key":"102_CR3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet"},{"issue":"5","key":"102_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Damme Van","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Pre-exposure prophylaxis for\u00a0HIV\u00a0infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"key":"102_CR5","unstructured":"McCormack S Dunn D, Gafos M, et al. Pragmatic Open-Label Randomised Trial of preexposure prophylaxis: the PROUD Study. 2015 conference on retroviruses and opportunistic infections (CROI), Seattle, USA, abstract 22LB; 2015."},{"key":"102_CR6","unstructured":"Molina J-M Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay Trial. 2015 conference on retroviruses and opportunistic infections (CROI), Seattle, USA, abstract 23LB; 2015."},{"key":"102_CR7","unstructured":"WHO: Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/186275\/1\/9789241509565_eng.pdf?ua=1 . Accessed Nov 11, 2015."},{"issue":"1","key":"102_CR8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAI.0b013e31828ece33","volume":"64","author":"LA Grohskopf","year":"2013","unstructured":"Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79\u201386.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"102_CR9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1086\/507306","volume":"194","author":"S Subbarao","year":"2006","unstructured":"Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2006;194:904\u201311.","journal-title":"J Infect Dis"},{"issue":"12","key":"102_CR10","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1371\/journal.pone.0050632","volume":"7","author":"J Radzio","year":"2012","unstructured":"Radzio J, Aung W, Holder A, et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS ONE. 2012;7(12):2012.","journal-title":"PLoS ONE"},{"issue":"11","key":"102_CR11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","volume":"14","author":"JM Baeten","year":"2014","unstructured":"Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14(11):1055\u201364.","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"102_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/QAD.0000000000000556","volume":"29","author":"RM Grant","year":"2015","unstructured":"Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331\u20137.","journal-title":"AIDS."},{"key":"102_CR13","unstructured":"Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20142014 Clinical Practice Guideline. Available from: http:\/\/www.cdc.gov\/hiv\/pdf\/PrEPguidelines2014.pdf ."},{"key":"102_CR14","unstructured":"Hatano H, et al. Lack of detectable HIV DNA in a PrEP study participant treated during \u201chyperacute\u201d HIV infection. 21st CROI. 3\u20136 March 2014, Boston. Late breaker poster 397LB. http:\/\/croiconference.org\/sites\/all\/abstracts\/397LB.pdf \u00a0(PDF). Accessed 1202015."},{"issue":"3","key":"102_CR15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","volume":"368","author":"T Le","year":"2013","unstructured":"Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier\u00a0HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"102_CR16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1110039","volume":"368","author":"S Fidler","year":"2013","unstructured":"Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3):207\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"102_CR17","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n A, Bacchus C, Hocqueloux L, et al. Post-treatment\u00a0HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.","journal-title":"PLoS Pathog"},{"issue":"3","key":"102_CR18","doi-asserted-by":"crossref","first-page":"e33948","DOI":"10.1371\/journal.pone.0033948","volume":"7","author":"J Ananworanich","year":"2012","unstructured":"Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and\u00a0HIV\u00a0reservoir seeding during acute\u00a0HIV\u00a0infection. PLoS ONE. 2012;7(3):e33948.","journal-title":"PLoS ONE"},{"key":"102_CR19","doi-asserted-by":"crossref","first-page":"e03821","DOI":"10.7554\/eLife.03821","volume":"3","author":"JP Williams","year":"2014","unstructured":"Williams JP, Hurst J, St\u00f6hr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821.","journal-title":"Elife."},{"issue":"7512","key":"102_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","volume":"512","author":"JB Whitney","year":"2014","unstructured":"Whitney JB, Hill AL, Sanisetty S, et al. Rapid\u00a0seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74\u20137.","journal-title":"Nature"},{"issue":"12","key":"102_CR21","doi-asserted-by":"crossref","first-page":"e1004543","DOI":"10.1371\/journal.ppat.1004543","volume":"10","author":"A Schuetz","year":"2014","unstructured":"Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543.","journal-title":"PLoS Pathog"},{"key":"102_CR22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/35035103","volume":"407","author":"ES Rosenberg","year":"2000","unstructured":"Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523\u20136.","journal-title":"Nature"},{"key":"102_CR23","doi-asserted-by":"crossref","unstructured":"Thornhill J Inshaw J, Oomeer S, et al. Enhanced normalisation of CD4\/CD8 ratio with early antiretroviral therapy in primary\u00a0HIV\u00a0infection. J Int AIDS Soc. 2014;17(4Suppl 3).","DOI":"10.7448\/IAS.17.4.19480"},{"issue":"3","key":"102_CR24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/QAI.0b013e3182829bd0","volume":"62","author":"A Jackson","year":"2013","unstructured":"Jackson A, Moyle G, Watson V, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. J Acquir Immune Defic Syndr. 2013;62(3):275\u201381.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"102_CR25","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/AAC.05317-11","volume":"55","author":"G Baheti","year":"2011","unstructured":"Baheti G, Kiser JJ, Havens PL, et al. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother. 2011;55(11):5294\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"102_CR26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of Tenofovir disoproxil fumarate blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"102_CR27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-med-050911-163701","volume":"64","author":"J Baeten","year":"2013","unstructured":"Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med. 2013;64:219\u201332.","journal-title":"Annu Rev Med"},{"key":"102_CR28","unstructured":"European Guidelines for treatment of HIV-infected adults in Europe 2015. Available from: http:\/\/www.eacsociety.org\/files\/guidelines_8_0-english_web.pdf . Accessed Nov 11, 2015."},{"issue":"8","key":"102_CR29","first-page":"1211","volume":"211","author":"DA Lehman","year":"2015","unstructured":"Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single or dual agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211\u20138.","journal-title":"J Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-015-0102-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T05:32:34Z","timestamp":1567488754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-015-0102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s40121-015-0102-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}